|
|
|
|
|
Legal status
Patent not validated
| (51) | INT.CL. | C07D 215/56 | |
| A61K 31/4704 | |||
| A61P 11/00 |
| (11) | Number of the document | 3204358 |
| (13) | Kind of document | T |
| (96) | European patent application number | 15849070.6 |
| Date of filing the European patent application | 2015-10-07 | |
| (97) | Date of publication of the European application | 2017-08-16 |
| (45) | Date of publication and mention of the grant of the patent | 2018-09-19 |
| (46) | Date of publication of the claims translation |
| (86) | Number | PCT/US2015/054577 |
| Date | 2015-10-07 |
| (87) | Number | WO 2016/057730 |
| Date | 2016-04-14 |
| (30) | Number | Date | Country code |
| 201462060828 P | 2014-10-07 | US |
| (72) |
STROHMEIER, Mark, US
CAESAR, JR., John P., US
CONNELLY, Patrick Raymond, US
FAWAZ, Majed, US
LUSS-LUSIS, Eduard, US
MCCLAIN, Brian R., US
MEDEK, Ales, US
MIAO, Hai, US
NTI-ADDAE, Kwame Wiredu, US
YIN, Ping, US
ZHANG, Yuegang, US
|
| (73) |
Vertex Pharmaceuticals Incorporated,
50 Northern Avenue, Boston, MA 02210,
US
|
| (54) | CO-CRYSTALS OF MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR |
| CO-CRYSTALS OF MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR |